Compare SMHI & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMHI | CHRS |
|---|---|---|
| Founded | 1989 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 179.4M | 186.0M |
| IPO Year | N/A | 2014 |
| Metric | SMHI | CHRS |
|---|---|---|
| Price | $6.68 | $1.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.02 |
| AVG Volume (30 Days) | 94.2K | ★ 961.1K |
| Earning Date | 10-29-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.34 |
| Revenue | $245,311,000.00 | ★ $277,728,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.81 | $67.29 |
| P/E Ratio | ★ N/A | $1.01 |
| Revenue Growth | N/A | ★ 152.07 |
| 52 Week Low | $3.63 | $0.71 |
| 52 Week High | $7.88 | $1.89 |
| Indicator | SMHI | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 44.14 | 51.35 |
| Support Level | $6.84 | $1.31 |
| Resistance Level | $7.47 | $1.41 |
| Average True Range (ATR) | 0.32 | 0.09 |
| MACD | -0.06 | 0.02 |
| Stochastic Oscillator | 18.95 | 68.93 |
Seacor Marine Holdings Inc provides marine and support transportation services to offshore energy facilities globally. The company operates and manages a diverse fleet of offshore support vessels that deliver cargo and personnel to offshore installations, including wind farms, handle anchors, and mooring equipment for offshore rigs and platforms. Its geographical segment includes the United States (Gulf of Mexico), Africa and Europe, Middle East and Asia, and Latin America.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.